At the time of vaccine administration, a frozen solution of E75 acetate (1.5 mg/mL) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. Patients randomized to this arm will receive vaccinations of nelipepimut-S/GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first vaccination will be given with the third dose of maintenance trastuzumab administered as monotherapy.
per clinical trial.
one would have to assume that your point is correct. Is NeuVax too simple a treatment to believe?
The market is either correct or blind.....time will tell.
Frost & Sullivan says the key treatments to watch between 2015 and 2017 are:
NeuVax (Galena Biopharma)
NKTR-102 (Nektar Therapeutics)
I would be skeptical if NeuVax showed clinical value in a single clinical trial. However, when 2 clinical trials are put thru the paces and the results show remarkable values from the use of NeuVax I leave skepticism aside and vote with my $$.
Cldx has gained 50% in a matter of weeks. Could Gale do the same?
These were positive events at one time now ........Friday 13 strikes again.
Chalk it up to a bad day.